@Article{096504017X15088061795756,
AUTHOR = {Yan-Sheng Gao, Xian-Zhi Liu, Yong-Gang Zhang, Xian-Jin Liu, Ling-Zhen Li},
TITLE = {Knockdown of Long Noncoding RNA LUCAT1 Inhibits Cell Viability  and Invasion by Regulating miR-375 in Glioma},
JOURNAL = {Oncology Research},
VOLUME = {26},
YEAR = {2018},
NUMBER = {2},
PAGES = {307--313},
URL = {http://www.techscience.com/or/v26n2/56642},
ISSN = {1555-3906},
ABSTRACT = {Recently, long noncoding RNAs (lncRNAs) have emerged as new gene regulators and prognostic markers 
in several cancers, including glioma. Here we focused on lncRNA LUCAT1 on the progression of glioma. 
qRT-PCR was used to determine the expression of LUCAT1 and miR-375 in glioma tissues and cells. MTT 
and Transwell invasion assays were performed to determine the function of LUCAT1 in glioma progression. 
The bioinformatics tool DIANA was used to predict the targets of LUCAT1. Pearson’s correlation analysis 
was performed to explore the correlation between LUCAT1 and miR-375. In the present study, we showed 
that LUCAT1 was substantially upregulated in glioma tissues and cells. LUCAT1 inhibition significantly 
suppressed the proliferation and invasion of glioma cells. Subsequently, DIANA showed that miR-375 was 
predicted to contain the complementary binding sites to LUCAT1. Luciferase reporter assay showed that 
miR-375 directly targeted LUCAT1. In addition, we found that miR-375 was downregulated in glioma tissues and negatively correlated with LUCAT1 expression in glioma tissues. Furthermore, the results showed 
that miR-375 could rescue the function of LUCAT1 in glioma progression. The lncRNA LUCAT1 was 
critical for the proliferation and invasion of glioma cells by regulating miR-375. Our findings indicated that 
LUCAT1 might offer a potential novel therapeutic target for the treatment of glioma.},
DOI = {10.3727/096504017X15088061795756}
}